Securing the exemption from CVA charges in the new bank capital rules within the EU was a crucial element of the EACT's campaign to ensure that OTC derivatives continued to be available to corporates for risk management and that the pricing remained competitive. Policy in the United States towards the CVA exemption has been and remains a concern to the EACT. In March, the EACT Chairman wrote to Mr Daniel Pinto, Co-CEO Corporate & Investment at JP Morgan, to seek clarity on the position of the bank with respect to the EU CVA exemption and to ask what action has been undertaken by the bank in the last six months. In his response, Mr. Pinto stated that JP Morgan has not called for a repeal of the CVA exemption for corporate end users, yet also expressed concern that the approach by the regulators was not globally consistent and, as such, creates competitive inequalities.
EACT Award 2022: And the Winner is... For the 3rd year in a row, the EACT recognises a project realised within the European Treasury Community.
View MoreWe wish you and your loved ones a happy holiday season and a new year filled with joy, prosperity and happiness.
View MoreThe European Association of Corporate Treasurers (EACT) announces the appointment of François Masquelier as its new Chair as from October 1st.
View MoreWe are delighted to announce that the sixth edition of the Journeys to Treasury report is now available to download.
View MoreThe latest edition contains the second EACT in Action event, treasury in the 'new normal', technological readiness of treasury in the Czech Republic, and more
View More